Hereditary Heparin Cofactor II Deficiency and the Risk of Development of Thrombosis

Summary

Heparin cofactor II (HC II) levels were measured by electroimmunoassay in healthy volunteers, and patients with liver disease, DIC, proteinuria or a history of venous thrombosis. Analysis of the data in 107 healthy volunteers revealed that plasma HC II increases with age (at least between 20 and 50 years). HC II was found to be decreased in most patients with liver disease (mean value: 43%) and only in some patients with DIC. Elevated levels were found in patients with proteinuria (mean value 145%). In 277 patients with a history of unexplained venous thrombosis three patients were identified with a HC II below the lower limit of the normal range (60%). Family studies demonstrated hereditary HC II deficiency in two cases. Among the 9 heterozygotes for HC II deficiency only one patient had a well documented history of unexplained thrombosis. Therefore the question was raised whether heterozygotes for HC II deficiency can also be found among healthy volunteers. When defining a group of individuals suspected of HC II deficiency as those who have a 90% probability that their plasma HC II is below the 95% tolerance limits of the normal distribution in the relevant age group, 2 suspected HC II deficiencies were identified among the healthy volunteers. In one case the hereditary nature of the defect could be established.

It is concluded that hereditary HC II deficiency is as prevalent among healthy volunteers as in patients with thrombotic disease. Further it is unlikely that heterozygosity for HC II deficiency in itself is a risk factor for the development of venous thrombosis.

Keywords

Heparin cofactor II deficiency - Thrombosis

• References

• 1 Abildgaard U. Highly purified antithrombin III with heparin cofactor activity. Scan J Clin Lab Invest 1968; 21: 89-91
• 2 Rosenberg RD. Heparin-Antithrombin system. In Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds.) J. B. Leppincott Company; Philadelphia-Toronto: 1982. pp 962-985
• 3 Thaler E, Lechner K. Antithrombin III deficiency and Thromboembolism. Clinics in Haematology 1981; 10: 369-390
• 4 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530
• 5 Vikydal R, Korninger C, Kyrle PA, Niessner H, Pabinger I, Thaler E, Lechner K. The prevalence of hereditary antithrombin III deficiency in patients with a history of venous thromboembolism. Thromb Haemostas 1985; 54: 744-745
• 6 Briginshaw GF, Shanberge JN. Identification of two distinct heparin cofactors in human plasma. I. Separation and partial purification. Arch Biochem Biophys 1974; 161: 683-690
• 7 Briginshaw GF, Shanberge JN. Identification of two distinct heparin cofactors in human plasma. II. Inhibition of thrombin and activated factor X. Thromb Res 1974; 4: 463-477
• 8 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
• 9 Wunderwald P, Schenk WJ, Port H. Anti-thrombin-BM from human plasma an antithrombin binding moderately to heparin. Thromb Res 1982; 25: 177-191
• 10 Jaffe EA, Armellino D, Tollefsen DA. Biosynthesis of functionally active heparin cofactor II by a human hepatoma-derived cell line. Biochem Biophys Res Comm 1985; 132: 368-374
• 11 Parker KA, Tollefsen DM. The protease specificity of Heparin-Cofactor II. J Biol Chem 1985; 260: 3501-3505
• 12 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin Cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
• 13 Abildgaard U, Larsen MI. Assay of dermatan sulfate cofactor (Heparin Cofactor II) activity in human plasma. Thromb Res 1984; 35: 257-266
• 14 Andersson R, Larson ML, Handeland GF, Abildgaard U. Heparin Cofactor II activity in plasma: Application of an automated assay method to the study of a normal adult population. Scan J Haematol. 1986; 36: 96-102
• 15 Griffith MJ, Carraway T, White GC, Dombrose FA. Heparin cofactor activity in a family with hereditary antithrombin III deficiency: Evidence for a second heparin cofactor in human plasma. Blood 1983; 61: 111-118
• 16 Tran TH, Marbet GA, Duckert F. Association of hereditary heparin cofactor II deficiency with thrombosis. The Lancet 1985; 413-414
• 17 Church FC, Noyes CM, Griffith MJ. Inhibition of chymotrypsin by heparin cofactor II. Proc Natl Acad Sci USA 1985; 82: 6431-6434
• 18 Síe P, Dupony D, Pichon J, Boneu B. Constitutional Heparin Co-factor II deficiency associated with recurrent thrombosis. The Lancet 1985; 414-416
• 19 Bertina RM, Broekmans AW, Krommenhoek-van EsC, Van Wijngaarden A. The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemost 1984; 51: 1-5
• 20 Bertina RM, Veltkamp JJ. A genetic variant of factor IX with decreased capacity for Ca²⁺binding. Br J Haematology 1979; 42: 623-635
• 21 Bertina RM, Broekmans AW, Van der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost 1982; 48: 1-5
• 22 Bertina RM, Van Wijngaarden A, Reinalda-Poot J, Poort SS, Bom V JJ. Determination of plasma protein S. The protein Cofactor of activated protein C. Thromb Haemost 1985; 53: 268-272
• 23 Eisenhart C, Hastay MW, Wallis WA. Techniques of Statistical Analysis. Mc Graw-Hill Book Company; New York: 1947. pp 102-107